2025
INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).
Motzer R, Braun D, Powles T, Gurney H, Fong L, George D, Haas N, McDermott D, Shuch B, Meehan R, Posadas T, Wu S, Elfiky A, Choueiri T. INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: tps610-tps610. DOI: 10.1200/jco.2025.43.5_suppl.tps610.Peer-Reviewed Original ResearchRenal cell carcinomaWeeks prior to randomizationAdverse eventsTumor-specific T-cell activationResection of metastatic lesionsAdjuvant treatment of patientsIncreased risk of recurrenceStage III/IV melanomaImmune checkpoint inhibitorsDisease-free survivalMetastasis-free survivalPhase 2 trialRisk of recurrenceDouble-blind studyT cell activationTreatment of patientsNovel combination strategiesDose of treatmentAdjuvant pembrolizumabAdjuvant settingCheckpoint inhibitorsPapillary histologyPD-1Sarcomatoid featuresMetastatic lesions
2024
Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures
Tanaka A, Ogawa M, Zhou Y, Namba K, Hendrickson R, Miele M, Li Z, Klimstra D, Buckley P, Gulcher J, Wang J, Roehrl M. Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures. Cell Reports 2024, 43: 113810. PMID: 38377004, PMCID: PMC11288375, DOI: 10.1016/j.celrep.2024.113810.Peer-Reviewed Original ResearchConceptsMetastatic colorectal adenocarcinomaModulation of major histocompatibility complexColorectal adenocarcinomaMetastatic progressionEpithelial-to-mesenchymal transition featuresPrimary colorectal adenocarcinomaTumor microenvironment analysisPrimary colorectal cancerCopy number alterationsProgression of colorectal adenocarcinomaAlternative telomere lengtheningTumor suppressor geneOncogenic pathway activationAntigen processing pathwayMajor histocompatibility complexProteomic subtypesLiver metastasesMetastatic lesionsImmune signaturesGenomic alterationsImmune evasionColorectal cancerMicroenvironment analysisSuppressor geneProteogenomic characterizationThe International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
Fong K, Rosenthal A, Giroux D, Nishimura K, Erasmus J, Lievens Y, Marino M, Marom E, Putora P, Singh N, Suárez F, Rami-Porta R, Detterbeck F, Eberhardt W, Asamura H, Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee M. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. Journal Of Thoracic Oncology 2024, 19: 786-802. PMID: 38320664, DOI: 10.1016/j.jtho.2024.01.019.Peer-Reviewed Original ResearchM1c patientsClassification of non-small cell lung cancerNon-small cell lung cancerLung Cancer Staging ProjectMultivariable-adjusted Cox proportional hazards regressionKaplan-Meier methodCell lung cancerCox proportional hazards regressionOrgan systemsProportional hazards regressionM1b categoryM1c categoryMetastatic categoriesMultiple metastasesMetastatic lesionsOverall survivalTNM classificationCurrent tumorLung cancerM categoryHazards regressionM descriptorsDecreased prognosisPotential confoundersMetastasis
2023
Gynecomastia in a Man With Adrenal Mass
Saini J, Navin P, Rivera M, Bancos I. Gynecomastia in a Man With Adrenal Mass. JCEM Case Reports 2023, 2: luad143. PMID: 38192879, PMCID: PMC10773200, DOI: 10.1210/jcemcr/luad143.Peer-Reviewed Original ResearchAdrenocortical carcinomaBilateral gynecomastiaEstrogen-secreting adrenal tumorRemoval of metastatic lesionsUltrasound-guided biopsyUrine steroid profileAdrenal malignancyDebulking surgeryLaparoscopic adrenalectomyAdrenal massAdrenal tumorsAdrenal insufficiencyMetastatic lesionsMultiple metastasesRare tumorInitial therapyMitotane therapyAdrenocortical adenomaEstrogen excessAndrogen precursorsEstrogen secretionGynecomastiaSurgical planningAndrogen metabolitesSteroid profileMetastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study
Ghali F, Vakar-Lopez F, Roudier M, Garcia J, Arora S, Cheng H, Schweizer M, Haffner M, Lee J, Yu E, Grivas P, Montgomery B, Hsieh A, Wright J, Lam H. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. Clinical Genitourinary Cancer 2023, 21: 669-678. PMID: 37344281, PMCID: PMC10674028, DOI: 10.1016/j.clgc.2023.05.014.Peer-Reviewed Original ResearchConceptsMetastatic urothelial carcinomaVariant histologySacituzumab govitecanTrop-2Nectin-4Antibody-drug conjugatesMetastatic lesionsADC targetCytoplasmic stainingProminent cytoplasmic stainingMembrane stainingTrop-2 expressionCytoplasmic protein expressionMetastatic sitesAutopsy studyUrothelial carcinomaMetastatic tumorsSquamous differentiationClinical relevanceCancer expressionHistologyNeuroendocrineProtein expressionMRNA levelsProtein levelsComparison of Percutaneous Interventional Ablation-Osteoplasty-Reinforcement-Internal Fixation (AORIF), Long Intramedullary Nailing, and Hemiarthroplasty for the Treatment of Focal Metastatic Osteolytic Lesions in the Femoral Head and Neck
Jiang W, Friedlaender G, Lindskog D, Latich I, Lee F. Comparison of Percutaneous Interventional Ablation-Osteoplasty-Reinforcement-Internal Fixation (AORIF), Long Intramedullary Nailing, and Hemiarthroplasty for the Treatment of Focal Metastatic Osteolytic Lesions in the Femoral Head and Neck. CardioVascular And Interventional Radiology 2023, 46: 649-657. PMID: 37052716, DOI: 10.1007/s00270-023-03425-x.Peer-Reviewed Original ResearchConceptsOsteolytic lesionsFemoral headSurgical complicationsRevision proceduresLong intramedullary nailingResultsSixty-seven patientsPost-operative complicationsEffective alternative treatmentTraditional surgical approachesAmbulatory scoreCombined painPrimary outcomeMedical complicationsMetastatic lesionsOncologic careRetrospective studyIntramedullary nailingSurgical approachFunction scoresNeck lesionsEarly improvementIM groupHemiarthroplastyComparative efficacyAlternative treatment
2022
Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer.
Kowalchuk R, Niranjan A, Hess J, Antonios J, Zhang M, Braunstein S, Ross R, Pikis S, Deibert C, Lee C, Yang H, Langlois A, Mathieu D, Peker S, Samanci Y, Rusthoven C, Chiang V, Wei Z, Lunsford L, Trifiletti D, Sheehan J. Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer. Journal Of Neurosurgery 2022, 138: 1608-1614. PMID: 36433878, DOI: 10.3171/2022.10.jns221900.Peer-Reviewed Original ResearchTriple-negative breast cancerLocal tumor progressionStereotactic radiosurgeryBreast cancerOverall survivalMetastatic lesionsPerformance statusLocal controlTriple-negative breast cancer metastasisMedian Karnofsky performance statusTumor progressionWhole-brain radiation therapyFavorable performance statusMedian margin dosePrior stereotactic radiosurgerySymptomatic radiation necrosisKarnofsky performance statusIntracranial metastatic diseaseRetrospective chart reviewLocal tumor controlBreast cancer metastasisIntracranial metastatic lesionsMargin doseMultiinstitutional cohortBrain metastasesOverview of the 2022 WHO Classification of Neuroendocrine Neoplasms
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens L, Ezzat S, de Herder W, Klimstra D, Papotti M, Asa S. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology 2022, 33: 115-154. PMID: 35294740, DOI: 10.1007/s12022-022-09708-2.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsNeuroendocrine neoplasmsSomatostatin receptorsWHO classificationNon-neuroendocrineDifferential diagnosisWHO Classification of EndocrineExpression of somatostatin receptorsWHO classification of neuroendocrine neoplasmsG3 neuroendocrine tumorsAssociated with germline mutationsPancreatic neuroendocrine tumorsClassification of neuroendocrine neoplasmsEctopic hormone productionLoss of RbLoss of ATRXSite of originComposite tumorMetastatic lesionsAberrant p53Amphicrine tumorsEpithelial neoplasmsPrecursor lesionsTheranostic biomarkersGermline mutationsFactors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry.
Alvi MA, Asher AL, Michalopoulos GD, Grills IS, Warnick RE, McInerney J, Chiang VL, Attia A, Timmerman R, Chang E, Kavanagh BD, Andrews DW, Walter K, Bydon M, Sheehan JP. Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry. Journal Of Neurosurgery 2022, 137: 985-998. PMID: 35171833, DOI: 10.3171/2021.10.jns211410.Peer-Reviewed Original ResearchMultivariable Cox proportional hazards analysisCox proportional hazards analysisAdministration of immunotherapyProportional hazards analysisStereotactic radiosurgeryIntracranial metastatic lesionsMetastatic lesionsOverall progressionLesion responseInitial stereotactic radiosurgeryMultifraction stereotactic radiosurgeryProgressive intracranial diseaseNeuro-Oncology criteriaOutcomes of patientsReal-world registryResponse Evaluation CriteriaGood local controlIntracranial metastatic diseaseKaplan-Meier analysisCommon primary tumorHazard of progressionLarger lesion sizeSingle-fraction treatmentLesion regressionMedian survival
2021
Epidermotropic metastasis of squamous cell carcinoma of the tonsil: A case report with molecular confirmation
Li P, Barbieri A, Walther Z, McNiff J, Panse G. Epidermotropic metastasis of squamous cell carcinoma of the tonsil: A case report with molecular confirmation. Journal Of Cutaneous Pathology 2021, 48: 1514-1519. PMID: 34302376, DOI: 10.1111/cup.14108.Peer-Reviewed Case Reports and Technical NotesConceptsSquamous cell carcinomaOropharyngeal squamous cell carcinomaCell carcinomaDe novo squamous cell carcinomaPrimary oropharyngeal squamous cell carcinomaTonsillar squamous cell carcinomaTargetable genetic aberrationsLesion biopsy specimensSkin biopsy specimenSkin lesion biopsy specimensMetastatic diseaseEpidermal involvementEpidermotropic metastasesMetastatic lesionsPoor prognosisBiopsy specimenCase reportClinical historyBiopsy specimensSecondary diseaseSkin lesionsTumor originMetastatic specimensMetastasisNeck skinOTHR-11. Comprehensive Analysis of Driver Mutation Profile in a Cohort of Lung Cancer Patients Using Targeted Gene Panel Analysis with Focus on Brain Metastatic Disease
Kazarian M, Cui J, Tocino I, Mahajan A, Aboian M. OTHR-11. Comprehensive Analysis of Driver Mutation Profile in a Cohort of Lung Cancer Patients Using Targeted Gene Panel Analysis with Focus on Brain Metastatic Disease. Neuro-Oncology Advances 2021, 3: iii16-iii16. PMCID: PMC8351181, DOI: 10.1093/noajnl/vdab071.066.Peer-Reviewed Original ResearchNon-small cell lung cancerBrain metastasesDeep white matterLung cancerGene panel analysisWhite matterLung cancer brain metastasesHospital tumor registryTertiary referral institutionCancer brain metastasesProportion of patientsBrain metastatic diseaseMajority of patientsBrain metastatic lesionsCell lung cancerLung cancer patientsLung cancer cohortTargeted Gene Panel AnalysisLung cancer diagnosisMolecular signaturesNext-generation sequencing resultsMetastatic diseasePatient demographicsTumor RegistryMetastatic lesionsPSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 5023-5023. DOI: 10.1200/jco.2021.39.15_suppl.5023.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPositive predictive valuePhase 3 studyPET/CTProstate cancerPrimary endpointPSA responseF-DCFPyL PET/CT scansF-fluciclovine PET/CTProspective phase 3 studyCorrelative imaging findingsRecurrent prostate cancerPET/CT accuracyConventional imaging modalitiesClinical trial informationDefinitive therapyLocal therapyBaseline imagingMetastatic lesionsImaging findingsAnatomic lesionsLower PSAF-DCFPyLTreatment responseCT scanComparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer
Moutafi MK, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross JS, Syrigos K, Wei W, Pusztai L, Rimm DL, Vathiotis IA. Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer. Journal For ImmunoTherapy Of Cancer 2021, 9: e002230. PMID: 33833050, PMCID: PMC8039214, DOI: 10.1136/jitc-2020-002230.Peer-Reviewed Original ResearchConceptsPD-L1 expressionMetastatic lesionsLung cancer casesLung cancerCancer casesAdvanced stage non-small cell lung cancerNon-small cell lung cancerNon-squamous histologyCell lung cancerFuture patient managementDefinite diagnostic testSquamous histologyFoundation MedicineLymph nodesRoutine careHistologic subtypeMetastatic sitesPrimary lesionRetrospective studyAdrenal glandPrimary tumorPleural fluidPatient managementTrial designDrug AdministrationP33.02 Comparison of PD-L1 Protein Expression Between Primary and Metastatic Lesions in Lung Cancer Patients
Moutafi M, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross J, Syrigos K, Wei W, Pusztai L, Rimm D, Vathiotis I. P33.02 Comparison of PD-L1 Protein Expression Between Primary and Metastatic Lesions in Lung Cancer Patients. Journal Of Thoracic Oncology 2021, 16: s405-s406. DOI: 10.1016/j.jtho.2021.01.671.Peer-Reviewed Original ResearchPSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 33-33. DOI: 10.1200/jco.2021.39.6_suppl.33.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPositive predictive valuePET/CTProstate cancerPrimary endpointPSA responseF-DCFPyL PET/CT scansF-fluciclovine PET/CTProspective phase 3 studyBiochemically recurrent prostate cancerCorrelative imaging findingsPhase 3 studyPhase III studyRecurrent prostate cancerPET/CT accuracyConventional imaging modalitiesDefinitive therapyIII studyLocal therapyMetastatic lesionsBaseline imagingImaging findingsAnatomic lesionsLower PSAF-DCFPyLDifferences in diagnostic impact of dual-tracer PET/computed tomography according to the extrahepatic metastatic site in patients with hepatocellular carcinoma
Yoo S, Kim D, Pyo A, Jeon S, Kim J, Kang S, Cho S, Lee C, Kim G, Song H, Bom H, Min J, Kwon S. Differences in diagnostic impact of dual-tracer PET/computed tomography according to the extrahepatic metastatic site in patients with hepatocellular carcinoma. Nuclear Medicine Communications 2021, 42: 685-693. PMID: 33625183, DOI: 10.1097/mnm.0000000000001382.Peer-Reviewed Original ResearchConceptsF-18 FDG PET/CTF-18 fluorodeoxyglucoseTracer PET/CTMetastatic lesionsLymph node lesionsExtrahepatic metastasesMetastatic sitesHepatocellular carcinomaC-11 acetateF-18Diagnostic performanceTracer avidityFDG-PET/CTPET/computed tomographyNode lesionsDetection of extrahepatic metastasesDiagnosis of extrahepatic metastasesMaximum standardized uptake valueF-18 FDG uptakeMetastatic lymph node lesionsExtrahepatic metastatic sitesStandardized uptake valueMetastatic bone lesionsSite of involvementSoft tissue
2020
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Journal For ImmunoTherapy Of Cancer 2020, 8: e001558. PMID: 33239417, PMCID: PMC7689582, DOI: 10.1136/jitc-2020-001558.Peer-Reviewed Original ResearchConceptsPD-L1 positivity ratePD-L1 positivityPD-L1 expressionDifferent metastatic sitesPrimary tumorMetastatic sitesPositivity rateImmune cellsMetastatic lesionsTumor cellsPD-L1 protein expressionTriple-negative breast cancerMore primary tumorsTriple negative breast cancer tumorsPrimary breast lesionsPrimary outcome measureSoft tissueNegative breast cancerLow positivity rateBreast cancer tumorsBone metastasesFoundation MedicineLymph nodesPD-L1Spearman correlation coefficientPhase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).
Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Drake C, Sosman J, Alter R, Plimack E, Rini B, Hurwitz M, Peace D, Signoretti S, Wu C, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). Journal Of Clinical Oncology 2020, 38: 5006-5006. DOI: 10.1200/jco.2020.38.15_suppl.5006.Peer-Reviewed Original ResearchRenal cell carcinomaProgressive diseaseStable diseaseGrade 3Sarcomatoid histologyPoor-risk renal-cell carcinomaAdvanced renal cell carcinomaMedian age 65Symptomatic progressive diseaseTreatment-related AEsTreatment-naïve patientsPhase II studyWk of treatmentEligible ptsImDC groupIpilimumab combinationMedian DoRMedian PFSSalvage therapyRespiratory failureSalvage treatmentII studyClinical outcomesMetastatic lesionsCell carcinomaDefining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward W. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy And Oncology 2020, 148: 157-166. PMID: 32388150, DOI: 10.1016/j.radonc.2020.04.003.Peer-Reviewed Original ResearchConceptsMetastasis-directed radiotherapyDefinition of oligometastatic diseaseOligometastatic diseaseMetastatic sitesAbsence of clinical dataMetachronous oligometastatic diseaseRadiation oncology perspectiveDisease-free intervalSingle-centre seriesContext of radiotherapyPatient inclusion criteriaProgression-freeMetastatic locationsCurative intentMetastatic lesionsOverall survivalPrimary tumorSystemic therapyOncological perspectiveQuality-of-lifeClinical dataRadiotherapyLocal controlConsensus documentInclusion criteriaPrognostic and Predictive Biomarkers in Oligometastatic Disease.
Barnum KJ, Weiss SA. Prognostic and Predictive Biomarkers in Oligometastatic Disease. The Cancer Journal 2020, 26: 100-107. PMID: 32205533, PMCID: PMC9208067, DOI: 10.1097/ppo.0000000000000438.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCirculating Tumor DNAClinical Decision-MakingDisease-Free SurvivalHumansMicroRNAsMutationNeoplasmsNeoplastic Cells, CirculatingPatient SelectionPrognosisProgression-Free SurvivalRadiofrequency AblationRadiosurgeryRisk AssessmentSurvival RateConceptsLocal therapyOligometastatic diseaseSystemic therapyPredictive biomarkersCurative-intent local therapyAdvanced disease stateCancer-related deathSurvival benefitPatient candidatesMetastatic lesionsPatient selectionPoor prognosisAblative treatmentClinical definitionTumor biologyTherapyOligometastasesDisease statesDiseasePatientsLocal interventionsBiomarkersPolymetastasesPrognosisLesions
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply